Ravuconazole

Ravuconazole (codenamed BMS-207147 and ER-30346) is a potent triazole antifungal, the development of which was discontinued in 2007.[1] The drug has shown to have a similar spectrum of activity to voriconazole, with an increased half-life.[2] However, ravuconazole has limited activity against species of Fusarium, Scedosporium, and Zygomycetes.[3][4]

Ravuconazole
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H17F2N5OS
Molar mass437.465086 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

See also

References

  1. "Ravuconazole". AdisInsight. Retrieved 12 November 2017.
  2. The Aspergillus Website, Pasqualotto AC, Denning DW. Ravuconazole. Date accessed: 2010 Feb 18.
  3. Pasqualotto AC, Thiele KO, Goldani LZ (2010). "Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole". Curr Opin Investig Drugs. 11 (2): 165–74. PMID 20112166.
  4. Pfaller, M. A.; Messer, S. A.; Hollis, R. J.; Jones, R. N.; Sentry Participants, Group (2002). "Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000". Antimicrobial Agents and Chemotherapy. 46 (4): 1032–7. doi:10.1128/AAC.46.4.1032-1037.2002. PMC 127116. PMID 11897586.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.